Fig. 3.
Effects of PPARδ treatment in an animal model of chronic left ventricular dysfunction following MI. A: increased fatty acid oxidation rate in response to PPARδ stimulation. B: changes in skeletal muscle gene expression with PPARδ stimulation. C: skeletal muscle ATP level changes, P = 0.38. D: no differences in skeletal muscle CSA. E: prolonged running time in animals following MI treated with a PPARδ agonist (*P < 0.05, **P < 0.01; placebo n = 5–9 and GW501516 n = 6 per analysis).